πŸ‡ΊπŸ‡Έ FDA
Patent

US 10259870

Anti-ANGPTL8 antibodies and uses thereof

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10259870 (Anti-ANGPTL8 antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2039/57, A61K39/39575